136 related articles for article (PubMed ID: 35650416)
1. Targeting CXCL5 in Pancreatic Cancer Cells Inhibits Cancer Xenograft Growth by Reducing Proliferation and Inhibiting EMT Progression.
Wang ZZ; Li XT; Li QJ; Zhou JX
Dig Dis Sci; 2023 Mar; 68(3):841-851. PubMed ID: 35650416
[TBL] [Abstract][Full Text] [Related]
2. Tumor-derived CXCL5 promotes human colorectal cancer metastasis through activation of the ERK/Elk-1/Snail and AKT/GSK3β/β-catenin pathways.
Zhao J; Ou B; Han D; Wang P; Zong Y; Zhu C; Liu D; Zheng M; Sun J; Feng H; Lu A
Mol Cancer; 2017 Mar; 16(1):70. PubMed ID: 28356111
[TBL] [Abstract][Full Text] [Related]
3. CXCR2/CXCL5 axis contributes to epithelial-mesenchymal transition of HCC cells through activating PI3K/Akt/GSK-3β/Snail signaling.
Zhou SL; Zhou ZJ; Hu ZQ; Li X; Huang XW; Wang Z; Fan J; Dai Z; Zhou J
Cancer Lett; 2015 Mar; 358(2):124-135. PubMed ID: 25462858
[TBL] [Abstract][Full Text] [Related]
4. Overexpression of CXCL5 is associated with poor survival in patients with pancreatic cancer.
Li A; King J; Moro A; Sugi MD; Dawson DW; Kaplan J; Li G; Lu X; Strieter RM; Burdick M; Go VL; Reber HA; Eibl G; Hines OJ
Am J Pathol; 2011 Mar; 178(3):1340-9. PubMed ID: 21356384
[TBL] [Abstract][Full Text] [Related]
5. CRISPR/Cas9-mediated deletion of Interleukin-30 suppresses IGF1 and CXCL5 and boosts SOCS3 reducing prostate cancer growth and mortality.
Sorrentino C; D'Antonio L; Ciummo SL; Fieni C; Landuzzi L; Ruzzi F; Vespa S; Lanuti P; Lotti LV; Lollini PL; Di Carlo E
J Hematol Oncol; 2022 Oct; 15(1):145. PubMed ID: 36224639
[TBL] [Abstract][Full Text] [Related]
6. CXCL5/ENA78 increased cell migration and epithelial-to-mesenchymal transition of hormone-independent prostate cancer by early growth response-1/snail signaling pathway.
Kuo PL; Chen YH; Chen TC; Shen KH; Hsu YL
J Cell Physiol; 2011 May; 226(5):1224-31. PubMed ID: 20945384
[TBL] [Abstract][Full Text] [Related]
7. The CXCL5/CXCR2 axis contributes to the epithelial-mesenchymal transition of nasopharyngeal carcinoma cells by activating ERK/GSK-3β/snail signalling.
Qiu WZ; Zhang HB; Xia WX; Ke LR; Yang J; Yu YH; Liang H; Huang XJ; Liu GY; Li WZ; Xiang YQ; Kang TB; Guo X; Lv X
J Exp Clin Cancer Res; 2018 Apr; 37(1):85. PubMed ID: 29665837
[TBL] [Abstract][Full Text] [Related]
8. MiR-301a transcriptionally activated by HIF-2α promotes hypoxia-induced epithelial-mesenchymal transition by targeting TP63 in pancreatic cancer.
Zhang KD; Hu B; Cen G; Yang YH; Chen WW; Guo ZY; Wang XF; Zhao Q; Qiu ZJ
World J Gastroenterol; 2020 May; 26(19):2349-2373. PubMed ID: 32476798
[TBL] [Abstract][Full Text] [Related]
9. Long non-coding RNA XLOC_000647 suppresses progression of pancreatic cancer and decreases epithelial-mesenchymal transition-induced cell invasion by down-regulating NLRP3.
Hu H; Wang Y; Ding X; He Y; Lu Z; Wu P; Tian L; Yuan H; Liu D; Shi G; Xia T; Yin J; Cai B; Miao Y; Jiang K
Mol Cancer; 2018 Jan; 17(1):18. PubMed ID: 29386037
[TBL] [Abstract][Full Text] [Related]
10. A novel antisense lncRNA NT5E promotes progression by modulating the expression of SYNCRIP and predicts a poor prognosis in pancreatic cancer.
Zhang P; Cao M; Zhang Y; Xu L; Meng F; Wu X; Xia T; Chen Q; Shi G; Wu P; Chen L; Lu Z; Yin J; Cai B; Cao S; Miao Y; Jiang K
J Cell Mol Med; 2020 Sep; 24(18):10898-10912. PubMed ID: 32770626
[TBL] [Abstract][Full Text] [Related]
11. MiR-652 inhibits acidic microenvironment-induced epithelial-mesenchymal transition of pancreatic cancer cells by targeting ZEB1.
Deng S; Li X; Niu Y; Zhu S; Jin Y; Deng S; Chen J; Liu Y; He C; Yin T; Yang Z; Tao J; Xiong J; Wu H; Wang C; Zhao G
Oncotarget; 2015 Nov; 6(37):39661-75. PubMed ID: 26498682
[TBL] [Abstract][Full Text] [Related]
12. HOXD9‑induced SCNN1A upregulation promotes pancreatic cancer cell proliferation, migration and predicts prognosis by regulating epithelial‑mesenchymal transformation.
Chang J; Hu X; Nan J; Zhang X; Jin X
Mol Med Rep; 2021 Nov; 24(5):. PubMed ID: 34558641
[TBL] [Abstract][Full Text] [Related]
13. High C-X-C motif chemokine 5 expression is associated with malignant phenotypes of prostate cancer cells via autocrine and paracrine pathways.
Qi Y; Zhao W; Li M; Shao M; Wang J; Sui H; Yu H; Shao W; Gui S; Li J; Jia X; Jiang D; Li Y; Zhang P; Wang S; Wang W
Int J Oncol; 2018 Jul; 53(1):358-370. PubMed ID: 29749439
[TBL] [Abstract][Full Text] [Related]
14. Synergistic effect of lung tumor-associated dendritic cell-derived HB-EGF and CXCL5 on cancer progression.
Kuo PL; Huang MS; Hung JY; Chou SH; Chiang SY; Huang YF; Yang CJ; Tsai MJ; Chang WA; Hsu YL
Int J Cancer; 2014 Jul; 135(1):96-108. PubMed ID: 24346967
[TBL] [Abstract][Full Text] [Related]
15. MicroRNA-494 acts as a tumor suppressor in pancreatic cancer, inhibiting epithelial-mesenchymal transition, migration and invasion by binding to SDC1.
Yang Y; Tao X; Li CB; Wang CM
Int J Oncol; 2018 Sep; 53(3):1204-1214. PubMed ID: 29956739
[TBL] [Abstract][Full Text] [Related]
16. Overexpression of CXCL5 mediates neutrophil infiltration and indicates poor prognosis for hepatocellular carcinoma.
Zhou SL; Dai Z; Zhou ZJ; Wang XY; Yang GH; Wang Z; Huang XW; Fan J; Zhou J
Hepatology; 2012 Dec; 56(6):2242-54. PubMed ID: 22711685
[TBL] [Abstract][Full Text] [Related]
17. HOXB5 promotes malignant progression in pancreatic cancer via the miR-6732 pathway.
Li ZX; Wu G; Jiang WJ; Li J; Wang YY; Ju XM; Yin YT
Cell Cycle; 2020 Jan; 19(2):233-245. PubMed ID: 31876226
[No Abstract] [Full Text] [Related]
18. Knockdown of CXCL5 inhibits the invasion, metastasis and stemness of bladder cancer lung metastatic cells by downregulating CD44.
Wang W; Zhang M; Huang Z; Wang L; Yue Y; Wang X; Lu S; Fan J
Anticancer Drugs; 2022 Jan; 33(1):e103-e112. PubMed ID: 34407043
[TBL] [Abstract][Full Text] [Related]
19. Activated CXCL5-CXCR2 axis promotes the migration, invasion and EMT of papillary thyroid carcinoma cells via modulation of β-catenin pathway.
Cui D; Zhao Y; Xu J
Biochimie; 2018 May; 148():1-11. PubMed ID: 29471001
[TBL] [Abstract][Full Text] [Related]
20. Serum CXCL5 level is associated with tumor progression in penile cancer.
Mo M; Li Y; Hu X
Biosci Rep; 2021 Jan; 41(1):. PubMed ID: 33458757
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
